MEDA acquires Rottapharm for about $3 Billion

MEDA acquires Rottapharm for about $3 Billion

MEDA acquires Rottapharm for about $3 Billion

Swedish drug maker Meda agrees to acquire Rottapharm, that operates under the name Rottapharm | Madaus in cash and stock deal for $3 Billion. (€ 2.275 Billion)

Rottapharm, founded in 1961, is the maker of Dona, which is used to manage pain associated with osteoarthritis; Legalon, a treatment for liver disorders; and Reparil, an anti-inflammatory drug and pain reducer. The company employs more than 2,000 employees in about 90 countries.

“The acquisition of Rottapharm is an important step in creating a stronger, improved Meda. Rottapharm is a preeminent company with highly differentiated brands and a leading position within Cx. The combination has an improved Rx / Cx balance and increased investment opportunities”, said Dr. Jörg-Thomas Dierks, CEO of Meda. “This acquisition is in line with our strategic priorities to execute value-accretive M&A, invest in consumer healthcare and Emerging Markets. We have been impressed by the business which the Rovati family has built up and we are honored to welcome the Rovati family as a major shareholder in Meda.”

Earlier this year, Meda rejected a takeover attempt by the American generic drug maker Mylan, which had hoped to reincorporate overseas to lower its corporate taxes in a so-called inversion.Mylan agreed in July to acquire the generic drug business of Abbott Laboratories outside the United States in an all-stock deal that valued the business at $5.3 billion and that will allow Mylan to engage in an inversion.

Meda advisors were Rothschild and the law firm Reed Smith and Rottapharm was advised by the law firm Pavesi Gitti Verzoni.

Mr. Stakebay says:

The combined company would have sales of 18 billion Swedish kronor ($2.62 billion) and create the leading European player in the Specialty Pharma sector.

 

CEO of MEDA …………………………….Jörg-Thomas Dierks…………………. (2005-present) …………………….SEK 2 900 000 (2013)

CEO of Rottapharm…………………………. Luca Rovati………………………… (2004-present)

 

MEDA

ROTTAPHARM

Revenue

SEK 8.027 Billion(2013)

€ 523.85 Million(2013)

Operating income

SEK 1.548 Billion(2013)

€ 108.55 Million(2013)

Profit

SEK 805 Million (2013)

€ 56.458 Million (2013)

Total assets

SEK 36.293 Million   (2013)

€ 1.426 Billion (2013)

Total Equity

SEK 15. 21Billion(2013)

€ 629.877 Million(2013)

Employees

3.062(2013)

1800 (2013)

 

 

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>